(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 17.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.72%.
Bicycle Therapeutics's revenue in 2025 is $28,339,000.On average, 17 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,279,151,591, with the lowest BCYC revenue forecast at $1,872,933,192, and the highest BCYC revenue forecast at $2,884,317,116. On average, 17 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,167,469,278, with the lowest BCYC revenue forecast at $212,751,337, and the highest BCYC revenue forecast at $4,370,177,448.
In 2027, BCYC is forecast to generate $3,466,452,499 in revenue, with the lowest revenue forecast at $197,143,560 and the highest revenue forecast at $9,127,427,756.